Do you really believe any other biotech would refuse to comment on one tiny regulator’s approval progress after any significant share price affecting amount of time (like beyond Accelerated approval )? Only in NWBO land. With no cutoff date to update shareholders and being overseas, it was actually a brilliant plan on her part.
Market Data 
Markets 
AI
